Price
$35.7
Decreased by -0.02%
Dollar Volume (20D)
31.79 M
ADR%
4.25
Earnings Report Date (estimate)
Aug 2, 23 (-0.69)
Market Cap.
3.82 B
Shares Float
103.64 M
Shares Outstanding
106.90 M
Beta
1.02
Price / Earnings
-24.97
BPR
217.27
20D Range
32.30 40.89
50D Range
24.05 42.48
200D Range
23.09 43.65
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
May 2, 23 0.45
Increased by +9.76%
-0.64
Increased by +266.11%
Feb 6, 23 -0.39
Increased by +35.00%
0.44
Decreased by -428.72%
Nov 28, 22 -0.81
Decreased by -32.79%
-0.17
Decreased by -2.21 K%
Aug 4, 22 -0.68
Decreased by -134.48%
-0.51
Decreased by -65.36%
May 10, 22 0.41
Increased by +257.69%
-0.08
Increased by +7.66 K%
Feb 2, 22 -0.60
Decreased by -200.00%
-0.45
Decreased by -74.07%
Nov 22, 21 -0.61
Decreased by -27.08%
-0.11
Decreased by -4.13 K%
Aug 5, 21 -0.29
Decreased by -123.08%
-0.20
Decreased by -225.00%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Mar 31, 23 146.27 M
Decreased by -3.65%
48.67 M
Increased by +9.71%
Increased by +33.28%
Increased by +13.87%
Dec 31, 22 62.55 M
Increased by +127.95%
-41.81 M
Increased by +33.50%
Decreased by -66.85%
Increased by +70.83%
Sep 30, 22 31.57 M
Decreased by -17.52%
-85.94 M
Decreased by -35.61%
Decreased by -272.18%
Decreased by -64.42%
Jun 30, 22 32.41 M
Decreased by -29.37%
-71.18 M
Decreased by -137.88%
Decreased by -219.62%
Decreased by -236.80%
Mar 31, 22 151.81 M
Increased by +362.66%
44.37 M
Increased by +265.43%
Increased by +29.23%
Increased by +135.76%
Dec 31, 21 27.44 M
Increased by +28.80%
-62.87 M
Decreased by -203.26%
Decreased by -229.13%
Decreased by -135.44%
Sep 30, 21 38.28 M
Increased by +401.56%
-63.37 M
Decreased by -30.85%
Decreased by -165.54%
Increased by +73.91%
Jun 30, 21 45.89 M
Increased by +67.63%
-29.92 M
Decreased by -119.85%
Decreased by -65.21%
Decreased by -31.15%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.